Compare Rush Street Interactive Inc (RSI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rush Street Interactive Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Rush Street Interactive Inc trades at $18.9 (market cap $2.35B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.3× Rush Street Interactive Inc's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rush Street Interactive Inc for 13 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| RSI | XBI | |
|---|---|---|
Market Cap | $2.35B | $10.11B |
Volume | 2,219,374 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $34.52 | $169.55 |
52-Week Low | $15.89 | $104.99 |
Typical Hold Time | 13 Days | 38 Days |
Enterprise Value | $2.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rush Street Interactive (RSI) trades at $20.32, up 0.4% on the day, with a bearish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates, and revenue growth from $1.13B in 2025 to $1.4B in 2026. Analyst consensus is bullish with a $34.88 price target, though net income margin compression from 2.93% to 2.33% highlights profitability challenges.
RSI presents a mixed outlook: robust revenue growth and solid analyst support contrast with thin margins and bearish technicals. The stock offers upside to consensus targets but faces execution risks in a competitive online betting market. Investors should weigh growth potential against margin pressures and market sentiment.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
